GBA1 Gene Therapy（Eli Lilly And Company）

N/A

Report date: 2023/10/26 16:14:54

Base Information

Drug NameGBA1 Gene Therapy（Eli Lilly And Company）
Drug Alias NameAAv9-GBA1（Eli Lilly And Company）AAv9-GBA1 Gene Therapy（Eli Lilly And Company）PR-001PR001ALY-3884961 +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionGene transferenceGlucosylceramidase replacements
TargetsGlucosylceramide
Therapy Area/IndicationsGaucher's disease type IIGaucher's disease type IGaucher Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And CompanyPrevail Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPrevail Therapeutics IncEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsGaucher's disease type IIGaucher's disease type IGaucher Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A